SEC Tracker
Get the app

Anaptysbio ANAB

Anaptysbio: quarterly report for the quarter ended Sep 30, 2022

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.23
Material contract
Exhibit 10.24
Material contract

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Anaptysbio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  2. Stoke Therapeutics STOK public float $592M, Jun 30, 2025
  3. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  4. ImmunityBio IBRX public float $690M, Jun 30, 2025
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.